Vertex Pharmaceuticals (WBO:VRTX) EPS (Basic): €14.61 (TTM As of Mar. 2026)


WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
90 GF Score
Price €410.10
GF Value €439.78
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals EPS (Basic)?

Vertex Pharmaceuticals WBO:VRTX +2.51% 90 EPS (Basic) is €14.61 as of Mar. 2026. GuruFocus rates WBO:VRTX with a GF Score™ of 90/100 and a GF Value™ of €439.78 (Fairly Valued). The stock has 4 warning signs investors should review.

Vertex Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €3.51. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €14.61.

Vertex Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was €3.48. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €14.49.

Vertex Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was €3.87. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 16.17.

During the past 3 years, the average EPS without NRI Growth Rate was 7.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -19.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Vertex Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 84.40% per year. The lowest was -96.70% per year. And the median was -1.25% per year.

Vertex Pharmaceuticals  (WBO:VRTX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Vertex Pharmaceuticals EPS (Basic) Related Terms

Vertex Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals EPS (Basic) Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.05 12.24 12.88 -1.99 13.20

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 3.49 3.61 4.01 3.51
WBO:VRTX
90GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Vertex Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(3376.033-0)/255.700
=13.20

Vertex Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(892.161-0)/254.100
=3.51

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €14.61 mean?
Vertex Pharmaceuticals (WBO:VRTX) has a EPS (Basic) of €14.61 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' EPS (Basic) too high?
Vertex Pharmaceuticals' current EPS (Basic) is €14.61. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' EPS (Basic) compare to REGN and ALNY?
Vertex Pharmaceuticals' EPS (Basic) of €14.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current EPS (Basic) is €14.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €439.78, compared to a current price of €410.10 — trading 6.7% below its estimated fair value. The current EPS (Basic) is €14.61. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current EPS (Basic) is €14.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €410.10 is trading 6.7% below its estimated GF Value™ of €439.78. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • EPS (Basic): €14.61
  • GF Value™: €439.78 vs. price of €410.10 (6.7% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score

Get the complete analysis for WBO:VRTX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€410.10
Price
€439.78
GF Value